Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects

Drug Metabolism and Disposition

Volumn 27, Issue 6, 1999, Pages 701-709

  Chu, Kai Min ^b   Hu, Oliver Yoa Pu ^a   Shieh, Shyh Ming ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PIMOBENDAN;

ARTICLE; CARDIOVASCULAR EFFECT; DRUG EFFECT; ELECTROCARDIOGRAPHY; ENANTIOMER; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PALPITATION; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REPRODUCIBILITY; VASODILATATION; VERTIGO;

ADMINISTRATION, ORAL; CARDIOTONIC AGENTS; ELECTROCARDIOGRAPHY; HEMODYNAMIC PROCESSES; HUMANS; INJECTIONS, INTRAVENOUS; MODELS, BIOLOGICAL; PYRIDAZINES; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; VASODILATOR AGENTS;

SIGMOIDEA;

EID: 0033017136     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Baumann G, Ningel K and Permanetter B (1989) Cardiovascular profile of UDCG 115 BS-pimobendane and reversibility of catecholamine subsensilivity in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 13:730-738.
2. Buhrer M, Maitre PO, Crevoisier C and Stanski DR (1990) Electroencephalographic effects of benzodiazepines. II. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. Clin Pharmacol Ther 48:555-567.
3. Chu KM, Shieh SM, Wu SH and Hu OYP (1992) Enantiomeric separation of a cardiotonic agent pimobendan and its major active metabolite, UD-CG 212 BS, by coupled achiral chiral normal-phase high-performance liquid chromatography. J Chromatogr Sci 30:171-176.
4. Chu KM, Shieh SM, Wu Sh and Hu OYP (1995a) Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese. Eur J Clin Pharmacol 47:537-542.
5. Chu KM, Shieh SM, Wu SH and Hu OYP (1995b) Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. Clin Pharmacol Ther 57:610-621.
6. Endoh M, Shibasaki T, Satoh H, Norota I and Ishihata A (1991) Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 Cl in canine ventricular myocardium. J Cardiovasc Pharmacol 17:365-375.
7. Evans MA, Shanks CA, Brown KF and Triggs EJ (1984) Pharmacokinetic and pharmacodynamic modelling with pancuronium. Eur J Clin Pharmacol 26:243-250.
8. Fujino K, Sperelakis and Solaro RJ (1988) Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 63:911-922.
9. Galeazzi RL, Benet LZ and Sheiner LB (1976) Relationship between pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther 20:278-289.
10. Garrison MW, Vance-Bryan K, Larson TA, Toscano JP and Rotschafer JC (1990)Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother 34:1925-1931.
11. Hagemeijer F, Brand HJ and Roth W (1989a) Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. J Cardiovasc Pharmacol 14:302-310.
12. Hagemeijer F, Brand HJ and van Mechelen R (1989b) Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemie or idiopathic dilated cardiomyopathy. Am J Cardiol 63:571-576.
13. Hammarlund MM, Odlind B and Paalzow LK (1985) Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 233:447-453.
14. Holford NH and Sheiner LB (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429-453.
15. Hull CJ, VanBeem BH, McLeod K, Sibbald A and Watson MJ (1978) A pharmacokinetic model for pancuronium. Br J Anaesth 50:1113-1123.
16. Kong AN, Ludwig EA, Slaughter RL, DiStefano PM, DeMasi J, Middleton E,Jr. and Jusko WJ (1989) Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther 46:616-628.
17. Mehvar R (1992) Stereochemical considerations in pharmacodynamic modeling of chiral drugs (letter). J Pharm Sci 81:199-200.
18. Oosterhuis B, Berge RJ, Sauerwein HP, Endert E, Schellekens PT and Boxtel CJ (1984) Pharmacokinetic-pharmacodynamic modeling of prednisolone-induced lymphocytopenia in man. J Pharmacol Exp Ther 229:539.
19. Reid JL and Meredith PA (1990) Concentration-effect analysis of antihypertensive drug responses. Hypertension 16:12-18.
20. Remme WJ, Wiesfeld AC, Look MP and Kruyssen HA (1989) Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction. J Cardiorasc Pharmacol 14: Suppl 2:S41-S44.
21. Renard M, Walter M, Liebens I, Dresse A and Bernard R (1988) Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. Chest 93:1159-1164.
22. 2+ sensitivity of contractile proteins. Circulation 73:III78-III84.
23. Ruegg JC, Pfitzer G, Eubler D and Zeugner C (1984) Effect on contractility of skinned fibres from mammalian heart and smooth muscle by a new benzimidazole derivative, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-y1]-5-methy 1-3(2H)-pyridazinone. Arzneimittel forschung 34:1736-1738.
24. Sahn DJ, DeMaria A, Kisslo J and Weyman A (1978) Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58:1072-1083.
25. Scholz H and Meyer W (1986) Phosphodiesterase-inhibiting properties of newer inotropic agents. Circulation 73:III99-III108.
26. Schmitz W, von der Leyen H, Meyer W, Neumann J and Scholz H (1989) Phosphodiesterase inhibition and positive inotropic effects. J Cardiovasc Pharmacol 14:s11-s14.
27. Schuttler J, Stanski DR, White PF, Trevor AJ, Horai Y, Verotta D and Sheiner LB (1987) Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man. J Pharmacokinet Biopharm 15:241-253.
28. Schwartz JB, Verotta D and Sheiner LB (1989) Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions. J Pharmacol Exp Ther 251:1032-1038.
29. Segre G (1968) Kinetics of interaction between drugs and biological systems. Farmaco [Sci] 23:907-918.
30. Sheiner LB (1985) Analysis of pharmacokinetic data using parametric models. II. Point estimates of an individual's parameters. J Pharmacokinet Biopharm 13:515-540.
31. Sheiner LB and Beal SL (1985) Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm 13:185-201.
32. Sheiner LB, Stanski DR, Vozeh S, Miller RD and Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371.
33. Stanski DR, Hudson RJ, Homer TD, Saidman LJ and Meathe E (1984) Pharmacodynamic modeling of thiopental anesthesia. J Pharmacokinet Biopharm 12:223-240.
34. Teichholz LE, Kreulen T, Herman MV and Gorlin R (1976) Problems in echocardiographic volume determinations: echocardiographic-angiographic correlation in the presence or absence of asynergy. Am J Cardiol 37:7-11.
35. Verdouw PD, Hartog JM, Duncker DJ, Roth W and Saxena PR (1986) Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Ear J Pharmacol 126:21-30.
36. Von Meel JC (1985) Cardiovascular effects of the positive inotropic agents pimobendan and sulmazole in vivo. Arzneimittelforschung 35:284-288.
37. Walter M, Liebens I, Goethals H, Renard M, Dresse A and Bernard R (1988) Pimobendan (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. Br J Clin Pharmacol 25:323-329.
38. Weiner DL (1986) NONLIN84/PCNONLIN: software for the statistical analysis of nonlinear models. Methods Find Exp Clin Pharmacol 8:625-628.
39. Yamaoka K, Nakagawa T and Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175.